EICHOR
● Active Not Recruiting
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Condition: Multiple Sclerosis · Sponsor: Hoffmann-La Roche
About this study
This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (120)
| North Central Neurology Associates | Cullman, Alabama, United States | — |
| Alabama Neurology Associates | Homewood, Alabama, United States | — |
| 21st Century Neurology | Phoenix, Arizona, United States | — |
| Profound Research, LLC | Carlsbad, California, United States | — |
| Stanford University Medical Center | Stanford, California, United States | — |
| Advanced Neurology of Colorado, LLC | Fort Collins, Colorado, United States | — |
| Neurology Associates, PA | Maitland, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| American Health Network Institute, LLC | Avon, Indiana, United States | — |
| University of Kansas Medical Center | Kansas City, Kansas, United States | — |
| The NeuroMedical Clinic of Central Louisiana | Alexandria, Louisiana, United States | — |
| Maine Medical Center | Scarborough, Maine, United States | — |
+ 108 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.